Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Includes thermostabilized Ebola vaccines
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Subscribe To Our Newsletter & Stay Updated
